Gene Therapy Clinical Trials
Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine may improve the ability to detect bladder cancer without invasive procedures.
PURPOSE: Diagnostic trial to study the effectiveness of microsatellite analysis of sediment in the urine in detecting bladder cancer in healthy participants, participants who have genitourinary conditions requiring cystoscopy, and patients who have bladder cancer.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- procedure: computed tomography
- procedure: cystoscopy
- genetic: loss of heterozygosity analysis
- genetic: microarray analysis
- genetic: microsatellite instability analysis
- other: cytology specimen collection procedure
- other: laboratory biomarker analysis
Eligibility
DISEASE CHARACTERISTICS:
- Group 1 (healthy volunteers):
- No prior or concurrent urologic disease or devices
- No genitourinary (GU) complaints, including urgency or frequency of urination
- Normal urinalysis and urine cytology
- Never smoked cigarettes regularly (i.e., ≥ 1 cigarette/day for ≥ 1 year)
- No suspected exposure to environmental bladder carcinogens for > 1 year,
including, but not limited to, the following occupations or exposures:
- Aluminum industry
- Aromatic amines
- Coal gasification
- Coal tars and pitches
- Coke plant
- Dye industry
- Leather industry
- Machinist
- Painter
- Rubber industry
- Truck, bus, or taxi drivers
- Group 2 (participants with condition(s) that lead to false-positive urinary bladder
cancer screening studies):
- GU complaints requiring cystoscopy
- No current GU malignancy
- At least 1 of the following conditions:
- Benign prostatic hypertrophy (International Prostate Symptom Score > 12)
- Foreign bodies (stones, stents, or catheters)
- Hematuria (gross or microscopic)
- GU infection (e.g., prostatitis, urinary tract infection, pyelonephritis,
urethritis) within the past 3 months and completed treatment
- No sign of infection at the time of study participation
- Group 3 (superficial bladder cancer patients):
- Histologically confirmed superficial bladder urothelial malignancy
- Primary or recurrent disease
- No nontransitional cell carcinoma of the bladder, upper tract tumors,
muscle-invasive tumors, or superficial disease for which local therapy is not
appropriate
PATIENT CHARACTERISTICS:
Age
- Over 40
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- See Disease Characteristics
Other
- No prior cancer except nonmelanoma dermatologic malignancy
- Prior bladder cancer allowed for group 3 patients
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
- Prior intravesical therapy for bladder cancer allowed for group 3 patients
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy
Surgery
- Not specified
Ages Eligible for Study
40 Years - 120 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ruth Lira
650723136
Not Recruiting